Lacerta Therapeutics Expands Executive Leadership Team

ALACHUA, Fla.–(BUSINESS WIRE)–Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: Kenneth Warrington, Jr., PhD, co-founder of Lacerta, has joined as the company’s Chief Technology Officer (CTO), and Darin Falk, PhD, former Vice President of Gene Therapy Programs at Lacerta, will now serve as the company’s Chief Scientific Officer (CSO). Both Warrington and Falk represent significant additions to CEO Edgar Rodriguez-Lebron’s executive team, and further illustrate Lacerta’s commitment to developing a constellation of gene-based therapies.

“Ken and Darin have been an integral part of our growth and direction as a company, and we are thrilled to utilize their expertise and leadership in our continued advancement,” stated Edgar Rodriguez-Lebron, PhD, Lacerta’s President and CEO.